Bone Loss Study Seeks Female Volunteers
A Duquesne University research team is seeking participants for a human clinical trial to examine whether a formulation of melatonin, strontium citrate and vitamins D3 and K2 can treat bone loss in women with a thinning-bone condition known as osteopenia.
Paula Witt-Enderby, a Duquesne professor of pharmacology, and Mark Swanson, a naturopathic physician, are seeking 20 female postmenopausal volunteers who've been diagnosed with osteopenia-related bone loss and who are considering treatment to increase bone density.
Each study participant will be asked to keep a diary and complete seven visits.
Participants also will receive two free scans to measure lumbar-spine and hip-bone density; free blood tests for bone formation cells, vitamin D3 and melatonin levels; free clinical health assessments, symptom and quality of life questionnaires; free study medications; and free parking.
Ms. Witt-Enderby conducted a human clinical trial three years ago that revealed that melatonin -- a natural molecule released nightly in the body and by a popular over-the-counter sleep aid -- helped to prevent bone loss in healthy women entering menopause.
Strontium also has been shown to promote healthful effects in most organs and tissues of the body, including bone. The team hypothesizes that strontium and melatonin will have a synergistic effect in bone greater than strontium alone and at a lower dose. Mr. Swanson said strontium's impact on bone formation is much more powerful than calcium.
Women interested in participating should send an email to firstname.lastname@example.org.
Founded in 1878, Duquesne is consistently ranked among the nation's top Catholic universities for its award-winning faculty and tradition of academic excellence. Duquesne, a campus of nearly 10,000 graduate and undergraduate students, has been nationally recognized for its academic programs, community service and commitment to sustainability. Follow Duquesne University on Facebook, Twitter and Instagram.